Comparative Pharmacology
Head-to-head clinical analysis: EKTERLY versus KADCYLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EKTERLY versus KADCYLA.
EKTERLY vs KADCYLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ekterly is a tissue-selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER) and induces conformational changes leading to ER degradation. It antagonizes ER-mediated gene transcription and signaling, thereby inhibiting ER-dependent breast cancer cell proliferation.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
10 mg orally once daily
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Steady state reached within 2 days. Accumulation negligible with once-daily dosing.
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Renal excretion accounts for 70% of elimination, with 30% hepatobiliary/fecal. Approximately 15% is excreted unchanged in urine; the remainder as glucuronide metabolites.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent